© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
April 27, 2020
Depending on the situation, individuals with IBD who develop COVID-19 may want to alter their medication.
April 22, 2020
Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.
April 20, 2020
Genentech is seeking approval for a 2-hour ocrelizumab (Ocrevus) infusion time in patients with relapsing or primary progressive multiple sclerosis.
April 08, 2020
Autoimmunity and certain autoimmune diseases have been increasing in prevalence in the United States.
April 06, 2020
Officials with the FDA have granted approval to ixekizumab (Taltz, Eli Lilly) injection, 80 mg/mL for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.
March 27, 2020
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
March 16, 2020
Approximately 1 million individuals are living with multiple sclerosis in the United States, according to the National MS Society.
February 10, 2020
Pharmacists can play an integral role in managing patients with inflammatory bowel disease (IBD) through medication management.
February 04, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
January 24, 2020
Evidence-based recommendations focus on immunomodulators, biologics, and small molecules for the management of ulcerative colitis.